About

Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience a range of symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance and fluid retention.

The burden of HF will continue to rise, due to population aging, population growth and improved treatment of HF and other cardiovascular disorders. As a result, clinicians will be increasingly challenged to develop treatment plans and care systems that reduce the high levels of morbidity and mortality experienced by these patients, both from their HF and other comorbidities.

Visit our Heart Failure Management Hub to discover a range of educational content to facilitate the use of SGLT-2 inhibitors and other guideline directed medical therapies as foundational treatment for HF.

Articles

Consensus is Possible: Initiation and Exchange of Oral Anticoagulants in Non-valvular Atrial Fibrillation, According to a Territorial Protocol in a Period of Time

Citation:

European Cardiology Review 2017;12(2):104.

A Novel Target Molecule of Nobiletin Derived from Citrus Peels has a Therapeutic Potency Against the Development of Heart Failure

Citation:

European Cardiology Review 2017;12(2):105.

Curcumin Analogue GO-Y030 Significantly Improves Pressure Overload-induced Heart Failure in Vivo

Citation:

European Cardiology Review 2017;12(2):106.

The Inhibitory Effects of Curcumin Glucuronide on p300-HAT Activity and Hypertrophic Phenylephrine-Induced Responses in Cardiomyocytes

Citation:

European Cardiology Review 2017;12(2):107.